• What is STENTYS’ activity?


    STENTYS is a medical technology company that is a pioneer in the development of innovative stents. Founded in 2006, the Company provides solutions for treating complex heart illnesses such as heart attacks.

  • What is a stent?


    A stent is a small metallic meshed tube that is implanted in a coronary artery in order to treat an obstruction or a narrowing of the artery. There are two types of stent; standard metal stents and drug-coated stents. They allow the artery’s diameter to be widened through their implantation via a minor operation lasting about half an hour.

  • What is the size of STENTYS’ target market?


    The heart-attack stent market targeted by STENTYS is worth an estimated 2.3 billion dollars in 2010, and represents an increasing and fast-growing share of the coronary stent market.

  • What are the advantages of the Stentys stent in this market?


    The Stentys stent is self-apposing and adapts to changes in the diameter of the artery in which it is apposed, thereby avoiding malapposition. It has been demonstrated that this risk, which is significant with a conventional stent (around 28% according to the "Apposition II" study made public on 22 September 2010), is completely eliminated by the Stentys stent. Furthermore, Stentys's self-apposing stent has received CE marking for the treatment of acute myocardial infarction, making it the only stent perfectly designed and indicated in the treatment of this condition. Lastly, thanks to a mesh made of micro-connectors, the Stentys stent avoids blocking access to the lateral coronary branches. These innovations are protected by a number of patents.

    The Stentys stent is now the most highly evolved and safest solution available to patients.

  • Where does this stent’s innovation lie?


    The STENTYS stent is made out of an alloy, Nitinol, that has exceptional elastic properties. Its mesh of patented micro-connecters also represents a major breakthrough on the coronary stent market.

  • Has your stent been the subject of clinical trials?


    A clinical programme aimed at proving the safety and efficiency of this technology has been launched. The first two stages (Apposition I and Apposition II trials) have given very positive results, and show that the STENTYS stent does indeed eliminate the risk of malapposition amongst the patients observed.

  • What do cardiologists think about the STENTYS stent?


    The STENTYS stent was designed following a state-of-the-art R&D programme and close collaboration with cardiologists, who acknowledge the STENTYS stent’s ability to eliminate malapposition in heart attack treatment.

  • What are the next STENTYS development stages?


    Having received CE certification and the authorisation to market its products in the European Union, STENTYS’ products are currently in the prelaunch phase during which a number of large-scale studies will confirm the results already obtained. This prelaunch phase will last around 2 years, and will enable STENTYS to establish itself as the benchmark treatment for heart attacks and to acceleration the marketing of its products.

  • Why did STENTYS decide to be listed?


    A STENTYS IPO will enable the Company to finance its development, and notably the APPOSITION III clinical trials on some 500 patients and the commercial launch of its products in Europe, and then in the United States and Canada.

  • Are there tax benefits associated with the purchasing of STENTYS shares?


    As STENTYS is listed on the NYSE Euronext Paris, there are no specific tax benefits associated with the purchasing of the Company’s shares.

  • Are the listed shares eligible for PEA personal equity plans?


    STENTYS shares are indeed eligible for PEA personal equity plans (although please note that shares whose subscription provides income tax reduction rights cannot also be part of a personal equity plan).

    Under certain conditions, the use of a PEA personal equity plan allows you to:

    - benefit, during the Plan’s lifespan, from exemption from income tax payments and charges on dividends and capital gains on placements carried out within the framework of a Plan, on condition that the resulting gains are reinvested within the framework of the Plan;

    - benefit, when closing (or partially withdrawing from) the Plan on condition that this is not carried out within the first five years, from income tax exemption on the net profit made within the framework of the Plan.

    However, gains (dividends or capital gains) recorded within the framework of a PEA personal equity plan are subject to applicable tax at the time the gain is recorded (currently 12.1%).

Contact Us

Get in touch for the latest product information.

Contact Us

Page ID 1228   |   Last edited 2017/10/16